Association between CYP17 T-34C (rs743572) polymorphism and breast cancer (BC) risk was controversial. In order to derive a more definitive conclusion, we performed this meta-analysis. We searched in the databases of PubMed, EMBASE and Cochrane for eligible publications. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to assess the strength of association between CYP17 T-34C polymorphism and breast cancer risk. Forty-nine studies involving 2,7104 cases and 3,4218 control subjects were included in this meta-analysis. In overall, no significant association between CYP17 T-34C polymorphism and breast cancer susceptibility was found among general populations. In the stratified analysis by ethnicity and source, significant associations were still not detected in all genetic models; besides, limiting the analysis to studies with controls in agreement with HWE, we also observed no association between CYP17 T-34C polymorphism and breast cancer risk. For premenopausal women, we didn't detect an association between rs743572 and breast cancer risk; however, among postmenopausal women, we observed that the association was statistically significant under the allele contrast genetic model (OR = 1.10, 95% CI = 1.03-1.17, P = 0
INTRODUCTION
Breast cancer (BC), the most frequent malignant neoplasm among female worldwide, accounts for approximate 25% of women malignant tumor. It is reported that 1.67 million people were diagnosed as BC ever year, therefore it has become a serious health issue, especially in the developing countries [1] . It is well known that the lifetime presence of the estrogen in the blood is an important pathogenic factor of BC, and this is in consistence with the low incidence of the breast cancer in males that is due to the lower estrogen levels and lower breast tissue volume. By now, researches on the status of hormone receptors and/or menopause associated with
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genetic alterations in BC risk have attracted an increasing number of attention, and lots of genes, including BRIPI, CHEK2, MDM, TGFB, TP53, BRCA1, BRCA2, and PTEN, and also several gene polymorphisms. Among genes of this family, CYP17, CYP19 and CYP1A1 have important functions in synthesis, metabolism and maintaining the levels of the androgen and estrogen hormones [2] . Previous published reasearches have demonstrated that estrogen act as a crucial role in the formation of BC; in addition, evidences have also been found about the positive role of cell surface receptors of estrogen in tumorigenesis [3] . Nevertheless, the precise mechanism behind estrogen in the formation of BC remains unknown. Previous studies have indicated that cytochrome P450c17α, which is a key enzyme in the synthesis of estrogen, and could increase the breast neoplasm risk [4] . The cytochrome P450c17α enzyme, predominantly catalyzes the formation of the precursor dehydroepiandrosterone (DHEA). Meanwhile, precursor DHEA could further be converted into estrogen through a succession of tissue-specific pathways [5, 6] . Estrogen, plays a vital part in the etiology of BC and identified the risk between estrogen and BC could well elucidate the biosynthesis and metabolism mechanisms. So far, more and more researches have demonstrated the correlation of estrogen-related genes genetic variations with BC risk. The CYP17T-34C (rs743572) polymorphism which is located on the human chromosome 10, in the 50-untranslated region has been most commonly reported [7] .
Many studies about the genetic mutations or SNP occurring in CYP17 gene could enhance CYP17's transcription rate and increase the enzyme cytochrome P450c17 level, resuling in an increasing number of bioavailable estrogen, which is likely to affect the risk and aggressiveness of BC [8] . But many previous article results between rs743572 mutations and BC risk remain conflicting: Han's research [9] revealed that no statistically meaningful correlation of rs743572 with risk of BC. However, significant correlation was found between rs743572 and BC risk in another research on the same theme [10] . Since few new high-quality investigations were published, we performed this study to take a more precise evaluation of rs743572 with the risk of BC.
RESULTS

The main feature of included studies
As showed in Figure 1 , 331 references were retrieved at first based on our selection strategy. 186 papers were remained after removing the duplicate reports. After reading titles and abstracts, we excluded 104 studies which were clearly unrelated. In the end, the whole of the rest of the papers were checked based on the inclusion and exclusion criteria. Finally, forty-nine studies on rs743572 and the risk of BC were eventually included in our study.
Thirteen articles showed the number of three genotypes (TT, TC, and CC) among premenopausal women, and thirteen studies report TT, TC, and CC number in postmenopausal women. Main information of included studies were shown in Table 1 . Among these qualified researches, seventeen were performed in Asians, twentyfive in Caucasians, one in Africans, one in both Asians and Caucasians, one in both Africans and Caucasians, and four in mixed ethnicity. Moreover, twenty-two studies were considered as moderate-quality studies (NOS scores of these researches were 4-6), and other twenty-seven studies were considered as high-quality studies (NOS scores of these studies were seven or above). Except for four included researches were not in agreement with HardyWeinberg equilibrium (HWE), genotype distributions in the control groups of other 45 researches were all satisfied with HWE.
Meta-analysis results
Meta-analysis results among overall populations, distribution of this polymorphism in case groups and control groups are presented in Table 2 . For premenopausal women and postmenopausal women, distribution of this polymorphism in case groups and control groups are presented in Table 3 , and the main outcome of our study are shown in Tables 4 and 5 .
In overall populations, the association of CYP17 T-34C polymorphism with BC susceptibility was studied in forty-nine researches including 27,104 cases and In premenopausal individuals, thirteen included researches with 2, 029 breast cancer case groups and 2, 920 control groups were eventually included. There is no statistical correlation of rs743572 with breast cancer susceptibility in T/C model, the TT/CC, the TC/CC, the TT+TC/CC, and the TT/TC+CC (OR = 1.02 with 95% CI 0.93-1.10, OR = 1.01 with 95% CI 0.85-1.20, OR = 0.97 with 95% CI 0.83-1.14, OR = 0.95 with 95% CI 0.81-1.10, and OR = 1.04 with 95% CI 0.92-1.18, respectively). In postmenopausal women, significant correlation was found in T/C model (OR = 1.10, 95% CI = 1.03-1.17, P = 0.003) ( 
Sensitivity analysis
Even though four researches included in our studies were not conformed to the HWE balance (P < 0.05), final consequences were not changed when we excluded the abovementioned four studies. Besides, after performing the sensitivity analysis, the pooled OR values were not statistically significant changed when we delete each of the researches, indicating that this study has good stability and reliability.
Heterogeneity analysis
Heterogeneity was obtained by Q statistic. When the P value more than 0.1 in the Q test, then the fixedeffect models were selected to conduct relevant statistical analysis; otherwise, random-effect models were selected.
Publication bias
No statistical evidence of publication bias was found in the Begg's test and Egger's test. What's more, funnel plot also did not show any evidence of obvious asymmetry (Table 4 ) (Figure 4 ).
DISCUSSION
With the popularization and the rapid development of technology in the field of medicine, people have a deeper recognition of breast cancer. However, the specific mechanisms of the occurrence and the development of this cancer remain unclear. It is well established that estrogen involves in the development of mammary gland and plays crucial role in initiating of BC [2] . Extensive evidences have also been demonstrated that lifetime exposure to endogenous and/or exogenous estrogen, increased the risk of the morbidity of breast cancer [11] . Besides, estrogen plays a positive role of cell surface receptors of in tumorigenesis [2, 3] . Significance of genes functioning in steroid hormone synthesis is well established in breast cancer susceptibility. CYP17, a commonly known gene could code for the cytochrome P450c17α enzyme that is one of the key enzymes participated in estrogen biosynthesis [4] . CYP17 T-34C polymorphism, in the region (5′-UTR) of CYP17, has been reported up-regulate CYP17 transcription in some studies but not in others [7] . The functional impact of the T/C change is still an unresolved mystery. Moreover several studies have reported conflicting results with respect to menopausal status and CYP17 polymorphism. Hence, for the purpose of acquire a more accurate assessment of the association 109  21  47  41  113  18  58  37  Bergman  109  15  62  32  117  9  55  53  Haiman  463  73  212  178  618  94  307  217  Huang  123  44  54  25  126  35  63  28  Young  39  5  13  21  58  7  28  23  Kristensen  510  67  241  202  201  26  101  74  Hamajima  144  20  83  41  166  27  95  44  Kuligina  240  47  111  82  182  44  77  61  Mitrunen  479  53  227  199  480  60  220  200  Feigelson  850  149  409  292  1508  227  739  542  Gudmundsdottir  500  60  247  193  395  66  173  156  Wu  188  69  82  37  671  229  333  109  Ambrosone  207  15  83  109  188  22  71  95  Tan  250  89  115  46  250  89  110  51  Hefler  388  75  186  127  1698  287  804  607  Ahsan  313  49  155  109  271  51  140  80  Chacko  140  6  40  94  140  3  22  115  Einarsdo´ttir  1499  238  711  550  1338  212  638  488  Shin  462  127  223  112  337  115  152  70  Verla-Tebit  527  103  244  180  904  157  424  323  Hopper  1404  230  621  553  788  113  364  311  Onland-More  335  44  140  151  373  50  157  166  Han  210  52  105  53  427  92  235  100  Piller  608  119  289  200  1298  236  596  466  Chakraborty  186  59  98  29  212  45  110  57  Setiawan  5147  833  2445  1869  6882  1070  3338 2474 www.impactjournals.com/oncotarget Chen  1037  168  506  363  1096  175  523  398  Sakoda  615  216  297  102  877  298  441  138  Zhang  299  84  168  47  242  73  125  44  Samson  250  32  91  127  500  54  226  220  Sangrajrang  564  96  281  187  489  92  230  167  Sobczuk  100  46  44  10  106  34  55  17  Antognelli  547  60  258  229  544  68  249  227  Hosseini  53  6  29  18  53  13  33  7  Jakubowska  319  45  166  108  290  54  136  100  MARIE-GENICA  3145  529  1573  1043  5487  941  2712 Wu  131  45  62  24  468  163  233  72  Ambrosone  111  8  52  51  102  12  43  47  Einarsdo´ttir  1499  238  711  550  1338  212  638  488  OnlandMore  335  44  140  151  373  50  157  166   Chen  680  111  339  230  677  96  333  248  Samson  134  16  50  68  197  23  99  75  Antognelli  360  42  177  141  314  37  150  127  Kato  109  20  55  34  115  16  48  51  Zhang  146  44  80  22  118  36  58 between rs743572 and BC risk we performed this metaanalysis whose included research studies identified in the PubMed, EMBASE and the Cochrane. In overall populations, our results indicate no significant correlation between rs743572 and the risk of BC. Similar results could be obtained when stratified by ethnicity in all ethnic groups. In addition, confining the analysis to the researches with control groups in consistent with HWE, we also observed no correlation between rs743572 and risk of BC. Nevertheless, meaningful correlation was showed between rs743572 and breast neoplasm risk in Russian individuals [10] . There were three meta-analyses, all published in 2010, including 24-43 papers from different populations and demonstrated no association between the rs743572 and BC, which further demonstrate that our results are credible [12, 13, 14] .
Estrogen is mainly produced in the ovaries and mammary glands among premenopausal women. However, in postmenopausal individuals, adipose tissue mainly acts as an important part in estrogen biosynthesis [15, 16] . Several studies have reported conflicting results of menopausal and CYP17 polymorphism: the study by Dunning et al. [17] showed the association between increased A2 genotype and premenopausal breast cancer; while Feigelson et al. [18] reported increasing frequency of A2 genotype associated with postmenopausal BC patients. We observed that rs743572 was correlated with an increasing BC risk among postmenopausal women under the allele contrast genetic model, but not in other models; however, no association was found in premenopausal women. Previous published meta-analysis reported that no association existed both in postmenopausal women and among premenopausal women [12, 13, 14] . Compared with them, our study used five genetic models to reduce the probability of class I errors, so our result was more reliable. Unavoidable, there are some limitations in metaanalysis. First, breast cancer is a multifactorial disease involving genetic and environmental interactions; however, it was still not addressed the impact of geneenvironmental interactions in this meta-analysis [19] . Second, the detailed individual information in some studies was unknown; thus, we could not assess the susceptibility of breast cancer according to other risk factors including obesity, family history, radiation therapy in young age, history of pregnancy, breast-feeding, hormone therapy and so on [20] . Last, there are only two studies about Africans, more well designed studies with different population should be performed to make more persuasive conclusions. In summary, our results indicate that rs743572 could increase risk of BC in postmenopausal individuals, but not in premenopausal women and the general population. Further multicenter research with complete risk factors are required to validate the potential role of rs743572 polymorphism in BC. More multicenter studies and complete risk factors are needed to further confirm the possible role of rs743572 polymorphism in the occurrence and development of breast cancer.
MATERIALS AND METHODS
Literature and search strategy
We searched the PubMed, EMBASE and Cochrane databases for studies performed prior to March 7, 2017 that reported an association between rs743572 SNP and breast cancer risk. There were no language restrictions in our searching process. The searching strategy was as follow: (breast cancer OR breast carcinoma) AND (polymorphism OR variant OR genotype OR SNP) AND (CYP17 OR CYP17A1 OR P450c17). Besides, the references of the retrieved studies were also reviewed to identify additional eligible studies.
Inclusion criteria
The included studies must meet the following criteria: (1) case-control design; (2) investigating the association between CYP17 T-34C polymorphism and breast cancer risk; (3) sufficient genotyping data that could be used to calculate odds ratios (ORs) and 95% confidence intervals (CIs); (4) all the breast cancer subjects in case groups must be pathologically confirmed. The exclusion criteria were: (1) not case-control studies; (2) review article or commentary; (3) duplicate studies; (4) studies lacking relevant data. 
Data extraction
Two reviewers independently extracted the relevant data from the included studies, and discrepancies were resolved during a discussion with a third author. The following information was extracted: the first author, year of publication, country, ethnicity, source of controls, number of cases and controls, and P value for Hardy-Weinberg equilibrium (HWE). In addition, we also evaluated the methodological quality of included studies based on Newcastle-Ottawa Scale (NOS), which scored studies according to three aspects: selection, comparability, and exposure. Therefore, all studies could be divided into three categories: "low quality" studies (score 0-3); "moderate quality" studies (score 4-6); "high quality" studies (score 7-9).
Statistical analysis
The association between CYP17 T-34C polymorphism and BC susceptibility was measured by pooled odds ratios (ORs) and 95% confidence intervals (CIs) in five genetic models, including an allele contrast genetic model, a homozygote genetic model, a heterozygote genetic model, a dominant genetic model, and a recessive genetic model. Pooled ORs were performed for homozygote comparison (TT vs. CC for rs743572), heterozygote comparison (TC vs. CC for rs743572), dominant model (TT/TC vs. CC for rs743572), recessive model (TT vs. TC/CC for rs743572) and allelic model (T vs. C for rs743572) respectively. Statistical heterogeneity was evaluated by I 2 test and Q test, P < 0.05 was considered statistically significant. For I 2 test, the criteria for heterogeneity were as follows: I 2 < 25%, no heterogeneity; 25%-75%, moderate heterogeneity; I 2 > 75%, high heterogeneity. If the P value of Q test was < 0.1, the random-effects model was used; otherwise, the fixed-effects model was applied. Sensitivity analysis was performed by excluding one study at a time to assess the influence of each study on the pooled ORs. Begg's funnel plot and Egger's tests were used to examine publication bias and to evaluate the stability of the results by sensitivity analysis. The P value for Hardy-Weinberg equilibrium (HWE) in controls of every included study was calculated by Chi-square test. Subgroup analysis was performed according to ethnicity. All statistical analyses were performed using STATA version 10.0 software (StataCorp LP, College Station, TX, USA). All P values were two sided, and P < 0.05 was considered statistically significant.
